Tags

Type your tag names separated by a space and hit enter

[Immunophenotyping in acute leukemia: detection of minimal residual disease].
Orv Hetil. 2000 Nov 12; 141(46):2487-92.OH

Abstract

Immunophenotyping improves both accuracy and reproducibility of the acute leukaemia classification and is considered particularly useful for identifying poorly differentiated subtypes of acute myeloid leukaemia and lineage association of acute lymphoid leukaemia. Immunological studies of leukaemic blasts has become critical also identifying biphenotypic leukaemias and acute myeloid leukaemia expressing lymphoid associated markers. At present, while the prognostic value of individual antigen expressions is still controversial, the immunologic detection of minimal residual disease seems to be important in monitoring the acute leukaemia patients in remission. In the present study immunophenotyping of bone marrow samples of 42 patients with acute myeloid leukaemia and 13 patients with acute lymphoid leukaemia was analysed. Patients were assessed both before and after treatment by immunophenotyping, cytogenetics and polymerase chain reaction amplification. The immunophenotyping have allowed more sensitive definition of acute leukaemia relapse, but molecular genetic methods are recommended for detection of elimination of residual disease.

Authors+Show Affiliations

Semmelweis Egyetem, Budapest, Egészségtudományi Kar, Immunológiai Tanszék.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

hun

PubMed ID

11126681

Citation

Pálóczi, K, et al. "[Immunophenotyping in Acute Leukemia: Detection of Minimal Residual Disease]." Orvosi Hetilap, vol. 141, no. 46, 2000, pp. 2487-92.
Pálóczi K, Nahajevszky S, Jakab K, et al. [Immunophenotyping in acute leukemia: detection of minimal residual disease]. Orv Hetil. 2000;141(46):2487-92.
Pálóczi, K., Nahajevszky, S., Jakab, K., Regéczy, N., Gopcsa, L., László, E., & Földi, J. (2000). [Immunophenotyping in acute leukemia: detection of minimal residual disease]. Orvosi Hetilap, 141(46), 2487-92.
Pálóczi K, et al. [Immunophenotyping in Acute Leukemia: Detection of Minimal Residual Disease]. Orv Hetil. 2000 Nov 12;141(46):2487-92. PubMed PMID: 11126681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Immunophenotyping in acute leukemia: detection of minimal residual disease]. AU - Pálóczi,K, AU - Nahajevszky,S, AU - Jakab,K, AU - Regéczy,N, AU - Gopcsa,L, AU - László,E, AU - Földi,J, PY - 2000/12/29/pubmed PY - 2001/3/3/medline PY - 2000/12/29/entrez SP - 2487 EP - 92 JF - Orvosi hetilap JO - Orv Hetil VL - 141 IS - 46 N2 - Immunophenotyping improves both accuracy and reproducibility of the acute leukaemia classification and is considered particularly useful for identifying poorly differentiated subtypes of acute myeloid leukaemia and lineage association of acute lymphoid leukaemia. Immunological studies of leukaemic blasts has become critical also identifying biphenotypic leukaemias and acute myeloid leukaemia expressing lymphoid associated markers. At present, while the prognostic value of individual antigen expressions is still controversial, the immunologic detection of minimal residual disease seems to be important in monitoring the acute leukaemia patients in remission. In the present study immunophenotyping of bone marrow samples of 42 patients with acute myeloid leukaemia and 13 patients with acute lymphoid leukaemia was analysed. Patients were assessed both before and after treatment by immunophenotyping, cytogenetics and polymerase chain reaction amplification. The immunophenotyping have allowed more sensitive definition of acute leukaemia relapse, but molecular genetic methods are recommended for detection of elimination of residual disease. SN - 0030-6002 UR - https://www.unboundmedicine.com/medline/citation/11126681/[Immunophenotyping_in_acute_leukemia:_detection_of_minimal_residual_disease]_ L2 - https://medlineplus.gov/acutemyeloidleukemia.html DB - PRIME DP - Unbound Medicine ER -